Artificial Intelligence for biological heterogeneity assessment of glioblastoma based on medical image analysis
Improving patient prognosis, predicting response to treatment
Multiparametric Tissue Signature
Heterogeneity assessment of the tumor by means of the detection of functional habitats within the lesion through state-of-the-art unsupervised machine learning analysis.access
Clinical trial services
Efficient patient stratification based on advanced imaging biomarkers can save up to 10% in a drug development cost in a clinical trial.
Technology patented P201431289
Artificial Intelligence technology to transform complex multi-parametric imaging data into clinically interpretable information.
The multiparametric tissue signature automatically captures the tumor heterogeneity, providing a set of functional habitats with high prognostic capabilities.
Open-access services for tumor heterogeneity assessment, implementing consolidated state-of-the-art techniques.